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ABSTRACT 
Objectives: The purpose of this study was to evaluate the clinical characteristics and compare the treatment efficacy of 
different types of cesarean scar pregnancy (CSP). 
Material and methods: We performed a retrospective chart review of 66 women (69 cases) with CSP who received treat-
ment with mifepristone/methotrexate (MTX) plus curettage, uterine artery embolization (UAE) plus curettage, additional 
MTX, or laparotomy, and compared the clinical characteristics, treatment efficacy, and occurrence of complications among 
3 types of CSP (partial, complete, and mass type). 
Results: Review of the 69 cases revealed a considerable increase of gestational duration(p < 0.001), sac/lesion size(p < 0.001) 
and vaginal bleeding (p < 0.05) in patients with mass-type CSP compared to that of other types. All CSP cases were success-
fully treated, 4 cases of mass-type received laparotomy and none of the cases required a hysterectomy. Severe bleeding 
was observed in 2 cases of partial-type and complete-type, respectively, and 3 cases for mass-type. Moreover, bleeding 
occurred during initial treatment with mifepristone plus curettage in partial-type cases, but not with UAE plus curettage. 
Conclusions: UAE plus curettage is a more effective treatment option for partial- and complete-type of CSP than mifepris-
tone plus curettage. The cases of mass-type often need surgery and are prone to have longer gestational duration, larger 
lesions, and more vaginal bleeding.
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INTRODUCTION
The increasing rate of cesarean section has attract-
ed worldwide concerns in recent decades [1]. The post-ce-
sarean era and requirement of two-child  policy in China 
has made the situation worse, although the occurrence of 
cesarean section without medical indication was controlled. 
Long-term complications of a cesarean section, such as 
diverticulum which induced prolonged menstruation and 
irregular vaginal bleeding, the complications and treat-
ment used in partial, complete, and mass-type CSP cases 
were shown in Table 1. The most severe complication, ce-
sarean scar ectopic pregnancy (CSP) which was defined as 
an ectopic pregnancy in which the fertilized egg is implant-
ed in the previous cesarean section scar, may cause uncon-
trollable bleeding, uterine rupture, hysterectomy, placenta 
previa, and can be life-threatening [2]. CSP was reported 
to be sporadic in case reports decades ago [3, 4]; however, 
in recent years there have been increased reports of CSP 
emerged, including randomized control trials (RCTs) [5–10], 
cohort studies [11–13], and comparative case studies [14]. 
Thus, CSP is no longer a rare form of ectopic pregnancy.
Table 1. Clinical features of the 69 CSP cases (n = 66)
Characteristic Mean ± SD (%)
Age [y] 32.39 ± 4.25 
No. of curettage [n] 1.75 ± 1.75
No. of prior cesarean delivery [n] 1.41 ± 0.52
Time since previous cesarean delivery, y [%] 1 (10.14%) ≥ 2 (89.86 %)
Gestational weeks at time of diagnosis 
[weeks] 7.75 ± 2.14 (5–16)
Presence of fetal heartbeat [n] 29.16 ± 17.43 (5–74)
Abdominal pain [n] 7 (10.14%)
Vaginal bleeding 39 (56.5%)
Data are presented as n, mean ± SD, median (range), or n (%)
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Currently, to the best of our knowledge, the consensus 
or guidelines on the diagnosis and treatment of CSP is un-
clear. Hence, a retrospectively study involving 69 cases of 
CSP (partial-, complete-, and mass-type CSP) was conducted 
to compare the clinical characteristics, treatment efficacy, 
and occurrence of complications among the different types.
MATERIAL AND METHODS
This is a retrospective case series of patients with diag-
nosis of CSP who treated at Chaohu Hospital (the Affiliated 
Chaohu Hospital of Anhui Medical University, Hefei, Anhui, 
PR China) from January 2016 to January 2019. Thirteen 
women were excluded because the absence of related clini-
cal characteristics, lost for follow-up or unclear ultrasound 
images, and 79 women diagnosed with CSP were selected 
based on the following criteria: clear ultrasound images, 
no absence of data or follow-up. Sixty-six women with CSP 
(69 cases) met the criteria were enrolled in the study. This 
study was approved by the Ethics Committee of the hospital 
(approval no. 201901-kyxm-02).
Clinical characteristics of the patients are summarized 
in Table 2 which include age, gestational weeks, pregnancy 
duration, abortion and curettage time, cesarean section time, 
interval since previous cesarean section, gestational sac/le-
sion size, fetal heartbeat, initial serum β-human chorionic 
gonadotropin β-(hCG) level, vaginal bleeding, and abdominal 
pain. The ultrasonographic images were evaluated based on 
the criteria [15], the abdominal and vaginal ultrasonographic 
instruments used were Mylab 90 of Baisheng (made in China) 
and GE-LOGIQ E9(made in America). According to the clas-
sification rules [16], diagnosis and treatment consensus [17] 
and mass type of CSP commonly observed in clinic [18], the 
69 cases were divided into 3 types: partial-, complete-, and 
mass-type. The partial-type is defined when the gestational 
sac is partially embedded in the myometrium of the scar, and 
a part or most of the gestational sac has grown toward the 
endometrial cavity, with the gestational sac deformed, elon-
gated, with a sharp angle at the lower end, and surrounded 
by vasculature. In complete-type CSP, the gestational sac 
is totally embedded in the myometrium of the scar, with 
an empty endometrial cavity and cervical canal surrounded 
by vasculature. Mass-type CSP is defined when there are 
mixed echoes located in the scar of the lower uterine seg-
ment, protruding toward the bladder, with the local muscular 
layer thinned, and abundant blood flow surrounding it. 
The clinical characteristics, treatment efficacy, and oc-
currence of complications were compared in all cases. Suc-
cessful treatment was considered as a reduction or disap-
pearance of the mass and/or significant normalization of 
the serum β-hCG level.
Several therapeutic approaches used for these cases in-
volving mifepristone or methotrexate (MTX) plus curettage; 
uterine artery embolization (UAE) plus curettage; additional 
MTX; and laparotomy treatment. Curettage was performed 
via the method of dilatation and suction with the guidance 
of ultrasound. The embolic agents used in UAE were gelatin 
sponge granules and sponge strips
Statistical analysis was performed using SPSS ver-
sion 19.0. Continuous variables were expressed as means 
standard deviations for normal distribution and median for 
non-normal distribution, statistical significance was tested 
using Student ‘s t-test and Mann–Whitney U-test, respective-
ly. One-way ANOVA followed by Bonferonni’s test was used 
to compare the difference among groups. Categorical data 
were presented as frequencies or percentages and com-
pared by Chi-square test or Fisher’s exact test. A two-sided 
p-value of 0.05 was considered statistical significance.
RESULTS
From January 2016 to January 2019, 69 cases of CSP(66 pa-
tients) were managed in our unit (1 case of partial-type and 
2 cases of complete-type turned into mass-type CSP after 
treatment, the initial and subsequent treatment of these 
3 cases were conducted in Chaohu Hospital). The clinical char-
acteristics of 69 cases are shown in Table 2. Of the 69 cases, 1 of 
them with partial-type CSP became pregnant 11 months after 
treatment with mifepristone-progesterone and curettage, 
additional methotrexate (MTX) with second curettage; she 
delivered a healthy female infant weighing 3675 g with an Ap-
Table 2. Clinical features of CSP in partial-type, complete-type, and 
mass-type cases
Characteristic Partial Complete Mass p-value
Case number [n] 33 28 8
Age [y] 
(mean ± SD)* 32.1 ± 4.4 33.2 ± 4.2 30.9 ± 3.6 0.326
No. of curettage 
(mean ± SD)* 1.30 ± 1.29 1.25 ± 1.17 1.50 ± 1.41 0.884
No. of prior 
cesarean delivery 
(mean ± SD)*
1.36 ± 0.55 1.50 ± 0.51 1.25 ± 0.46 0.407
Time since 
previous 
cesarean delivery 
[y]#
1 4 3 0 0.867
≥ 2 29 25 8
Gestational weeks 
(mean ± SD)* 7.24 ± 1.58 7.43 ± 1.75 11.0 ± 2.78 < 0.001*
Presence of fetal 
heartbeat# 13 7 0 0.273
Abdominal pain# 2 4 1 0.442
Vaginal bleeding# 18 13 8 0.019*
*ANOVA test; #Chi-squared test
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gar score of 9 at 1 min and 10 at 5 min via cesarean section 
at term. Placenta previa and partial adhesion were observed 
during the operation, and the estimation of blood loss was 
400 mL. Another case was a recurrent scar pregnancy diag-
nosed in 15 months ago, where she underwent treatment 
with mifepristone combined with uterine curettage.
Sixty-nine cases of CSP, including 33 partial-type cas-
es, 28 complete-type cases, and 8 mass-type. Among the 
8 mass-type cases, 1 case was diagnosed by transvaginal 
ultrasound, presenting menopause of 50 days with vaginal 
bleeding. The other 7 cases were diagnosed after medical 
intervention such as suction curettage or drug-induced 
abortion, and the time of diagnosis varies from hours to 
2 months. Out of 7 cases 3 received initial and subsequent 
treatment at the same hospital, whereas the other 4 cases 
received initial treatment at other hospitals. The ultrasono-
graphic images of the 3 types of CSP were shown in Figure 1.
The clinical characteristics of patients among the 3 CSP 
subgroups were shown in Table 2. We found there were no 
significant differences in age, curettage times, cesarean sec-
tion times and intervals, gestational weeks, cardiac activities, 
gestational sac/lesion size, vaginal bleeding, and abdominal 
pain between partial- and complete-type CSPs. Compare 
to the partial- and complete-type of CSP, the gestational 
duration was significantly increased (p < 0.001), so was the 
sac/lesion size (p < 0.001) and vaginal bleeding (p < 0.01) in 
mass-type patients, but there was no significant difference 
in age, curettage times, cesarean section times and intervals, 
as well as abdominal pain. 
All of 69 CSP cases were successfully treated with one 
or more combined treatments. There were 12 of 33 cases 
with partial-type CSP initially treated with mifepristone plus 
curettage, and 10 cases were successful treated in which 
2 cases received additional MTX, moreover, 2 cases received 
UAE due to bleeding during the treatment. The success rate 
of treatment with mifepristone plus uterine curettage ± MTX 
in partial-type CSP was 83.3% (10/12). The initial treatment 
with UAE plus curettage of twenty cases were successful 
which presented no excessive bleeding. Therefore, the 
success rate of UAE plus curettage in partial-type CSP was 
100.0% (20/20). One case referred from other institutions 
had been previously misdiagnosed as intrauterine preg-
nancy and artificial abortion was performed directly. After 
that, the repeated vaginal bleeding occurred for 2 months 
until the second time to hospital and was misdiagnosed with 
trophoblastic neoplasm before the surgical treatment was 
performed, it has been confirmed as CSP by the intraopera-
tive findings and postoperative pathology. 
In the group with complete-type of CSP, 6 of 28 first-con-
sulted patients were successfully treated with drug plus 
curettage (4 with mifepristone, and 2 with MTX). The other 
22 were treated with UAE and curettage initially in which 
20 cases (including 1 case that accepted additional MTX) 
underwent successful treatment, whereas 2 had a stable 
pregnancy (mass-type) later. As a result, the success rate of 
UAE plus curettage with or without MTX in complete-type 
CSP was 90.9% (20/22).
Figure 1. Ultrasound images of the 3 types of CSP. A, partial type. B, 
complete type. C and D, mass type
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In the group with mass-type of CSP, 4 of 8 were treated 
with UAE plus curettage and 1 with additional MTX. The 
laparotomy was performed in other 4 cases; 1 case was the 
preceding partial-type CSP which was misdiagnosed ini-
tially, and turned into a mass-type after a medical abortion, 
and the other 3 cases treated with MTX, of which 2 were pre-
ceding complete-type CSP which underwent treatment of 
UAE plus uterine curettage. All 4 surgeries were performed 
by laparotomy and scar repair, and no severe bleeding was 
observed during operation. 
As one of the major complications, hysterectomy had 
not been observed in any cases of our series, the com-
plications and treatment used in partial, complete, and 
mass-type CSP cases were shown in Table3. As showed 
in our data, moderate  bleeding (> 200 mL) occurred in 
4 partial-type, 3 complete-type, and 1 mass-type case, 
while severe bleeding (> 500 mL) occurred in 2 partial-type, 
2 complete-type, and 3 mass-type cases. However, patients 
of partial-type experienced bleeding during the initial treat-
ment of mifepristone combined with curettage, but not for 
the treatment regimen of UAE plus curettage which showed 
no severe bleeding. In 2 complete-type and 3 mass-type 
of patients developed bleeding during the UAE plus curet-
tage ± MTX.
DISCUSSION
In our study, we found that vaginal bleeding is the most 
common symptom among patients in CSP. Mass-type CSP 
cases are prone to have longer gestational duration, larger 
lesions, and more vaginal bleeding than partial- and com-
plete-type. In addition, we noted that UAE plus curettage 
is a more effective therapeutic approach than mifepris-
tone plus curettage which is the basic treatment for CSP. 
Moreover, most of the mass-type CSPs were developed from 
complete- and partial-type CSP after medical treatment and 
surgery is unavoidable to remove lesions.
A retrospective case-control study by Luo et al. [19] has 
shown that 58.7% of CSP cases experience vaginal bleeding 
and 15% experience abdominal pain as early symptoms. Kim 
et al. [20] reported that 53.4% of CSP cases had no symptoms 
around gestational weeks 6.5 ± 1.1. In our study, 39 (56.5%) 
cases experienced vaginal bleeding and 7 cases (10.14%) 
experienced abdominal pain, which were consistent with the 
previous reports. Approximately half of the CSP patients had 
no obvious early symptoms, based on these reports and our 
results we strongly recommended to pay more attention to 
patients after cesarean section, especially when they experi-
ence vaginal bleeding. Timor-Tritsch et al. [21] have suggested 
that routine ultrasound screening for CSP should be per-
formed in pregnant women with a history of cesarean section 
at gestational weeks 5–7 like screening for aneuploidy and 
preeclampsia. Early detection of CSP is critical to prevent its 
progression and improve the long-term prognoses.
The clinical features of CSP differ among different 
types. Our study showed that there were no significant dif-
ferences in age, curettage times, cesarean section times and 
intervals, gestational weeks, cardiac activities, gestational 
sac/lesion size, vaginal bleeding, and abdominal pain be-
tween partial- and complete-type CSP. However, the results 
indicated that the characteristics of mass-type CSP involving 
the occurrence in later gestational week, a larger lesion, 
vaginal bleeding tendency, and it often develops from par-
tial- and complete-type CSP after medical treatment, which 
is consistent with the previous report of Ying et al. [22].
To the best of our knowledge, CSP represents a diagnos-
tic and therapeutic challenge for the unclear guidelines of 
the classification and treatment till date. Our study showed 
that in partial-type CSP, the success rate of treatment with 
mifepristone plus curettage ± MTX was 83.3% (10/12), and 
17 cases were successfully treated with UAE plus curettage. 
The success rate of treatment with UAE plus curettage ± MTX 
in complete-type CSP was 90.9% (20/22). This result was 
Table 3. Treatment modalities and complications in partial, complete, and mass-type CSP cases
Type Initial treatment (n)
Successful 
with no 
intervention
Successful with 
additional MTX
Success rate 
(initial treatment 
+ additional MTX)
Eventual success with 
UAE or laparotomy, 
or became mass type
Bleeding (mL)
>200 >500
Partial
Mifepristone plus curettage (12) 7 3 83.3% (10/12) UAE (2) 4 2
UAE plus curettage (0) 20 0 100% (20/20) 0 0 0
Direct induced abortion (1) 0 Turned into mass (1)
Complete
Mifepristone plus curettage (4) 4 0 2 0
Additional MTX plus curettage (2) 2 0 1 0
UAE plus curettage (22) 19 1 90.9% (20/22) Turned into mass (2) 0 2
Mass
UAE plus curettage (4) 3 1 1 1 1
MTX (3) 0 laparotomy (3) 0 2
Laparotomy(1) 1 0 0
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consistent with that of previous reports [7, 23]. However, 
the safety of the patients, who underwent UAE treatment, 
to become pregnant again is under controversial. The risks 
include ovarian failure, infertility, abortion, premature de-
livery, and postpartum hemorrhage [24, 25]. However, in 
other cases, such as partial-type CSP with a thicker mus-
culature, UAE should be used when emergency massive 
hemorrhage occurs or as a second-line treatment instead 
of routine treatment.
The curative effect didn’t show an increase with the 
treatment of uterine curettage followed by MTX, in addition, 
it showed the ability to prolong the length of hospitalization 
[26]. MTX should not be used as an initial treatment because 
the fibrous tissue surrounding the gestational sac reduces 
the absorption and effectiveness of MTX [27]. However, as 
a remedy, MTX has a certain success rate due to the viability 
of trophoblasts. In our study, 4 of 6 cases of partial- and 
complete-type CSP received additional MTX which had 
been successfully treated. 
A previous report [12] has shown that the thinner the 
uterine myometrium between the gestational sac and the 
bladder, the treatment would be more difficult, and the more 
likely to have a surgery with more complications. Because 
there was no description of muscle thickness in some images 
in our retrospective study, it was not possible to further clas-
sify complete-type CSP. The mass-type in our study appeared 
to be a large lesion, protruding toward the bladder, with 
a thin muscular wall and abundant blood flow. In our study, 
4 of 8 cases with mass-type CSP underwent UAE; 3 were 
successfully treated and 1 required additional MTX with 
success. The remaining 4 were eventually treated surgically. 
In our series, three cases of mass-type CSP developed severe 
bleeding during treatment with UAE plus curettage and MTX, 
but not with an operation. Therefore, for the treatment of 
mass-type CSP, surgery was the most recommended option 
to remove the lesions because it would increase the possibil-
ity to bleeding and prolong the recovery time.
The mean gestational duration in our study was 
7.75 ± 2.14 weeks, and an early diagnosis contributed to the 
early treatment. None of the 69 cases underwent hysterec-
tomy, and seven of 8 cases of mass-type CSP developed after 
abortion or drug interference. Therefore, β-hCG levels and 
ultrasound should be monitored regularly after abortion of 
scar pregnancy in case the occurrence of pregnancy. Surgery 
is unavoidable once mass-type CSP develops. Although sur-
gical treatment is considered the optimal treatment choice, 
medical drug plus curettage can achieve similar results for 
patients who have non-mass-type CSP with a thicker scar 
and with low economic status to undergo surgery. Thus, 
how to remove the pregnancy safety and effectively, and 
to reduce the bleeding and injury to prevent hysterectomy 
in CSP cases are need for further study. 
There are some limitations in our study. There is no de-
scription of muscle thickness and blood flow in some images 
in our retrospective study, it is not possible to further typing 
complete CSP. We did not make comparisons of β-hCG for 
the levels of β-hCG (e.g. > 10,000 IU/L, other than a defined 
figure such as 12,000 mIU/mL) were not given for some CSP 
patients. In addition, the therapeutic approaches of UAE in 
partial-type CSP were slightly more, and which may affect 
credibility to some extent. 
In conclusion, UAE combined with curettage is a more 
effective treatment instead of mifepristone plus curettage, 
which is the basic treatment for partial- and complete-type 
CSP. Mass-type CSP has features such as occurrence at late 
gestational duration, larger lesion size, and more vaginal 
bleeding tendency. Most mass-type CSPs develop from 
partial- and complete-type CSPs after medical treatment, 
and many cases require surgery to remove the lesions. Im-
proper treatment may induce the increase of bleeding and 
impede the patients’ recovery.
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